The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Association of cytokine levels and reductions in spleen size in COMFORT-II, a phase III study comparing ruxolitinib to best available therapy (BAT).
Claire N Harrison
Consultant or Advisory Role - Celgene; Novartis; S Bio; Sanofi ; YM BioSciences
Stock Ownership - Celgene; Novartis; S Bio; Sanofi ; YM BioSciences
Honoraria - Celgene; Novartis; S Bio; Sanofi ; YM BioSciences
Research Funding - Novartis
Expert Testimony - S Bio
Jean-Jacques Kiladjian
Research Funding - Celgene; Novartis; Shire
Heinz Gisslinger
No relevant relationships to disclose
Francesco Passamonti
Consultant or Advisory Role - Celgene; Novartis; Sanofi
Honoraria - Celgene; Novartis; S Bio; Sanofi ; YM BioSciences
Research Funding - Novartis
Expert Testimony - S Bio
L. Andres Sirulnik
Employment or Leadership Position - Novartis
Ling Wang
Employment or Leadership Position - Novartis
Matthew Squires
Employment or Leadership Position - Novartis
Laurent Knoops
Consultant or Advisory Role - Novartis
Expert Testimony - Novartis
Giovanni Barosi
No relevant relationships to disclose
Tiziano Barbui
No relevant relationships to disclose
Francisco Cervantes
Consultant or Advisory Role - Advisoryt Board